Cytyc Announces First ThinPrep Imaging System Placement in U.K.

MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC), a leading women's health company, today announced it has placed the first ThinPrep(R) Imaging System in the United Kingdom (U.K.) at The Doctors Laboratory (TDL) in London. TDL is the largest clinical pathology service in the independent healthcare sector in the U.K. The TDL contract with Cytyc U.K. Ltd. is for a term of five years, and represents a potential of approximately 200,000 Imaged ThinPrep(R) Pap Tests during that period.

TDL's pathology service provides a wide range of diagnostic tests for general practitioners, consultants, clinics, hospitals, speciality and screening companies, occupational health departments, insurers, pharmaceutical product trials, laboratories as well as esoteric test referrals from Central London and throughout the U.K. TDL introduced the ThinPrep(R) Pap Test to its clientele in June 2000 and provides a rapid cervical cytology service to its diverse customers by consistently reporting test results within 48 hours.

"We are pleased to be Cytyc's first U.K. site to implement the ThinPrep Imaging System," said David Byrne, chief executive officer of The Doctors Laboratory. "This enables TDL to further improve their commitment to quality and speed of service in this key area of diagnostics."

"We have found the ThinPrep Imaging System to be a reliable and most beneficial aid for rapid accurate interpretation of ThinPrep cervical cytology," said Colin Clelland, M.D, TDL's consultant pathologist. "It has been easily accepted by the screening staff and has improved workflow significantly. Implementation and training went smoothly and any concern we had about the imager stain, which is specific to this product, was soon dispelled once we became familiar with it. We quickly became confident in the use of the Imaging System -- a most valuable asset for the laboratory."

Patrick J. Sullivan, Cytyc's chairman, president, and chief executive officer, said, "We are very happy to be working with TDL as the first laboratory to implement the ThinPrep Imaging System in the U.K. TDL is a long-time customer and we are delighted to continue to support TDL's ongoing focus on quality and maintaining the highest standards."

TDL joined Sonic Healthcare, one of the world's largest clinical pathology companies, three years ago. Sonic has laboratories in Australia, New Zealand, Germany, and the U.K.

Cytyc Corporation is a leading women's health company that designs, develops, manufactures, and markets innovative and clinically effective products. Cytyc products cover a range of women's health applications, including cervical cancer screening, breast cancer risk assessment, treatment of excessive menstrual bleeding, and treatment of breast cancer.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc, ThinPrep, FirstCyte, NovaSure, and MammoSite are registered trademarks of Cytyc Corporation.

Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to Cytyc's future financial condition, operating results and economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel, customers, and proprietary technology, uncertainty of product development efforts and product acceptance, management of growth and product diversification, entry into new market segments, risks associated with litigation and the determination of the amount of the final award for the DEKA Products Limited Partnership arbitration, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and healthcare reimbursement policies, introduction of technologies that are disruptive to Cytyc's business and operations, the impact of new accounting requirements and governmental rules and regulations, as well as other risks detailed in Cytyc's filings with the Securities and Exchange Commission, including under the heading "Certain Factors Which May Affect Future Results" in its 2004 Annual Report on Form 10-K filed with the Commission. Cytyc cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Cytyc disclaims any obligation to publicly update or revise any such statements to reflect any change in its expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.